Inactive Instrument

Medifocus, Inc.

Equities

MDFZF

CA58470Q1019

Medifocus Inc. Announces Election of Tak Cheung Yam as a Member of the Board of Directors; Reports Revenue Results for the Quarter Ended September 30, 2012

December 06, 2012 at 04:15 pm EST

Medifocus Inc. announced the election of Mr. Tak Cheung Yam as a member of the Board of Directors of the company at the company's annual and special meeting held on November 28, 2012.

The company reported revenue results for the quarter ended September 30, 2012. For the quarter ended September 30, 2012, the company reported its first ever revenue of $313,281 from sales of its Prolieve(R) System.

Latest news about Medifocus, Inc.

Medifocus Inc. Announces Resignation of Mirsad Jakubovic as Chief Financial Officer	20-08-21	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-03-02	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-29	CI
Medifocus Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-29	CI
Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	19-07-30	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-28	CI
Medifocus, Inc. Announces Global Market Expansion with Prolieve Performed and Reimbursed by Insurance Carriers in Hong Kong	19-01-03	CI
Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling	18-12-03	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2018	18-11-13	CI
Medifocus Inc. Reports Unaudited Consolidated Earnings Results for the Quarter Ended June 30, 2018	18-09-13	CI
Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study for the Prolieve (R) Thermodilatation(Tm) System	18-06-05	CI
Medifocus Inc. Enters into an Exclusive Distribution Agreement with Amos Gazit, Ltd to Market and Distribute Proven Prolieve® Thermodilatation System	18-01-09	CI
Medifocus, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017	17-08-28	CI
Medifocus, Inc. Auditor Raises 'Going Concern' Doubt	17-07-30	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	17-03-16	CI
Medifocus Inc. Reports Operating Results for the Six Months Ended September 30, 2016	16-12-19	CI
Medifocus Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended September 30, 2016	16-12-07	CI
Medifocus Inc. Appoints William Jow as Chief Executive Officer to Replace Augustine Y. Cheung	16-10-03	CI
Medifocus Inc. Announces Board Changes	16-09-14	CI
Medifocus Inc. Announces Earnings Results for the First Quarter Ended June 30, 2016	16-09-14	CI
Medifocus Inc. Auditor Raises 'Going Concern' Doubt	16-06-09	CI
Medifocus Inc.(TSXV:MFS) dropped from S&P/TSX Venture Composite Index	16-01-18	CI
Medifocus Inc. Signs Research &Development and Manufacturing Agreement with Yuanxing Bio-Pharm Science &Technology Co. Ltd	16-01-13	CI
Medifocus Inc. announced that it has received $0.79 million in funding	15-12-13	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2015	15-12-07	CI

Chart Medifocus, Inc.

Duration

Period

More charts

Company Profile

Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.

Sector

More about the company